Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
作者信息
Mango Natalie A, Pierson Sheila K, Sarmiento Bustamante Mateo, Brandstadter Joshua D, van Rhee Frits, Fajgenbaum David C
机构信息
Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Am J Hematol. 2024 Jan;99(1):E15-E18. doi: 10.1002/ajh.27132. Epub 2023 Oct 23.
Abstract
摘要
相似文献
1
Siltuximab administration results in spurious IL-6 elevation in peripheral blood.使用西妥昔单抗会导致外周血中白细胞介素-6（IL-6）出现假性升高。
Am J Hematol. 2024 Jan;99(1):E15-E18. doi: 10.1002/ajh.27132. Epub 2023 Oct 23.
2
The Role of Interleukin-6 in Castleman Disease.白细胞介素-6在Castleman病中的作用。
Hematol Oncol Clin North Am. 2018 Feb;32(1):23-36. doi: 10.1016/j.hoc.2017.09.003.
3
JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.与皮肤型Castleman病对司妥昔单抗的特殊反应相关的JAK1基因改变
JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554.
4
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.一项评估 siltuximab（一种抗 IL-6 单克隆抗体）在 B 细胞非霍奇金淋巴瘤、多发性骨髓瘤或 Castleman 病患者中的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性研究。
Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.
5
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.一项关于司妥昔单抗（一种抗白细胞介素-6单克隆抗体）在多中心Castleman病患者中安全性的2期开放标签多中心研究。
Oncotarget. 2015 Oct 6;6(30):30408-19. doi: 10.18632/oncotarget.4655.
6
Therapy of Castleman's disease with siltuximab - case report and review of literature.西妥昔单抗治疗 Castleman 病 1 例报告并文献复习
Klin Onkol. 2023 Winter;36(4):320-329.
7
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.特发性多中心 Castleman 病抗 IL-6 单克隆抗体治疗（西妥昔单抗）反应的预测因素：Ⅱ期临床试验数据的二次分析。
Br J Haematol. 2019 Jan;184(2):232-241. doi: 10.1111/bjh.15588. Epub 2018 Sep 11.
8
Siltuximab: first global approval.西妥昔单抗：全球首次批准。
Drugs. 2014 Jul;74(10):1147-52. doi: 10.1007/s40265-014-0249-x.
9
The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.白细胞介素 6 中和抗体对类风湿关节炎和多中心 Castleman 病患者情绪低落和快感缺失症状的影响。
Brain Behav Immun. 2017 Nov;66:156-164. doi: 10.1016/j.bbi.2017.06.014. Epub 2017 Jul 1.
10
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.新诊断和先前接受过治疗的多中心Castleman病对司妥昔单抗的反应相同。
Br J Haematol. 2021 Jan;192(1):e28-e31. doi: 10.1111/bjh.17177. Epub 2020 Oct 31.
引用本文的文献
1
Curative Gastrectomy for Advanced Gastric Cancer in a Patient with Idiopathic Multicentric Castleman Disease: A Rare Case Report.特发性多中心Castleman病患者晚期胃癌的根治性胃切除术：一例罕见病例报告
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.25-0318. Epub 2025 Jul 1.
2
Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy.特发性多中心Castleman病 - TAFRO综合征导致高水平的mTOR激活剂SVEP1、组织因子和内皮病变。
Blood Vessel Thromb Hemost. 2024 Jun;1(2). doi: 10.1016/j.bvth.2024.100006. Epub 2024 Apr 3.
3
Idiopathic multicentric Castleman disease and connective tissue disorder successfully treated by siltuximab: a pediatric case report.西妥昔单抗成功治疗特发性多中心Castleman病和结缔组织病：一例儿科病例报告
Transl Pediatr. 2024 May 31;13(5):824-832. doi: 10.21037/tp-23-605. Epub 2024 May 28.
4
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.免疫治疗的非小细胞肺癌患者血浆蛋白质组学的生物学见解。
Front Immunol. 2024 Feb 29;15:1364473. doi: 10.3389/fimmu.2024.1364473. eCollection 2024.
本文引用的文献
1
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.CXCL13 是特发性多中心 Castleman 病的预测性生物标志物。
Nat Commun. 2022 Nov 24;13(1):7236. doi: 10.1038/s41467-022-34873-7.
2
Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.西妥昔单抗可改善特发性多中心 Castleman 病的无进展生存期。
Blood Adv. 2022 Aug 23;6(16):4773-4781. doi: 10.1182/bloodadvances.2022007112.
3
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.特发性多中心Castleman病中一个新亚组及治疗靶点的发现与验证
Blood Adv. 2021 Sep 14;5(17):3445-3456. doi: 10.1182/bloodadvances.2020004016.
4
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
5
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.在接受CAR T细胞治疗后使用托珠单抗和/或西妥昔单抗治疗的患者血清中测量白细胞介素-6（IL-6）和可溶性白细胞介素-6受体（sIL-6R）。
J Immunol Methods. 2016 Jul;434:1-8. doi: 10.1016/j.jim.2016.03.005. Epub 2016 Apr 3.
6
Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.在食蟹猴中运用机制性药代动力学/靶点结合/药效学（PK/TE/PD）模型解析单克隆抗体与其可溶性靶点之间的相互作用
AAPS J. 2014 Jan;16(1):129-39. doi: 10.1208/s12248-013-9545-8. Epub 2013 Nov 28.
Zotero 插件